| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.075 | 0.01 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.01 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | 0.69 | 0.01 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |